Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease
Authors:
- 4 September 2014
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 55 (2) , 221-229
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Confirmatory analysis for phase III population pharmacokineticsPharmaceutical Statistics, 2011
- Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targetsmAbs, 2010
- Population Pharmacokinetics of Golimumab, an Anti‐Tumor Necrosis Factor‐α Human Monoclonal Antibody, in Patients With Psoriatic ArthritisThe Journal of Clinical Pharmacology, 2009
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologicsExpert Opinion on Drug Metabolism & Toxicology, 2009
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque PsoriasisThe Journal of Clinical Pharmacology, 2009
- Estimating the predictive quality of dose–response after model selectionStatistics in Medicine, 2007
- Inference After Model SelectionJournal of the American Statistical Association, 2004
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002